BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05984199 (VCAR33 in Relapsed or Refractory AML After Allogeneic…): BVCT ex-ante prediction vs. reported outcome

On 7 Nov 2023, BioinvestGPT's BVCT predicted technical success and commercial failure for this trial. The 8 May 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably insignificant and commercially probably insufficient.

Clinical Trial

NCTID
NCT05984199
Drug Name
VCAR33
Drug MoA
allogeneic anti-CD33 CAR-T cell therapy
Drug Modality
cell therapy
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Human Patients
38
Sponsor
Vor Biopharma
Phase
Phase 1 Phase 2

Prediction of , index 1317

Prospective Prediction
Prediction Index
1317
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
548 days in advance
Readout Data Interpretation
VCAR33’s further development has been discontinued
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably insignificant and commercially probably insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Phase
Phase 1, Phase 2
Status
Terminated
Enrollment
38
Lead sponsor
Vor Biopharma
Conditions
Leukemia, Myeloid, Acute
Interventions
BIOLOGICAL: VCAR33
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2023-12-11
Primary completion
2025-05-28
Completion
2025-05-28
Primary outcomes
  • Incidence of dose-limiting toxicities (Day 28)

NCT05984199 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials